Clinical trials: Recurrent Herpes Labialis
Herpes Labialis
Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
To compare safety and efficacy of Perrigo's antiviral drug product compared to an FDA approved antiviral drug product in the treatment of cold sores.
- Trial name
- NCT02265913
- Testing
- Acyclovir 5 percent (Perrigo), Acyclovir 5 percent (Reference)
- Where
- United States
- Volunteers
- 4,076 people
- Sponsor
- Padagis LLC
Recurrent Herpes Labialis
A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis
The study is designed to assess the efficacy and safety of patient-initiated therapy with famciclovir 1500 mg o.d. or 750 mg b.i.d. for one day treatment in adult men and women with recurrent herpes labialis
- Trial name
- NCT00248144
- Testing
- Famciclovir
- Sponsor
- Novartis
Herpes Labialis
NB-001 Treatment of Recurrent Herpes Labialis
This is a study to test the hypothesis that time to healing of a cold sore will be lower in the active treatment arm of the study when compared to the vehicle (placebo).
- Trial name
- NCT01695187
- Testing
- NB-001 (0.3%)
- Where
- 12 sites in United States
- Volunteers
- 362 people
- Sponsor
- NanoBio Corporation
Recurrent Herpes Labialis
A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)
The purpose of this study is to demonstrate the safety and efficacy of NB-001 in subjects with recurrent herpes labialis (RHL).
- Trial name
- SHaRCS (NCT01324466)
- Testing
- NB-001, Vehicle
- Where
- 35 sites in United States
- Volunteers
- 847 people, healthy volunteers welcome
- Sponsor
- NanoBio Corporation
Herpes Labialis
Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
Randomized, double-blind, multi-center, three arm parallel group, comparative trial to assess pritelivir ointment safety and efficacy, ie, proportion of subjects with non-ulcerative lesions, in adult subjects with recurrent…
- Trial name
- LipP1 (NCT02871492)
- Testing
- Pritelivir 5% w/w ointment, Zovirax® cream
- Where
- 10 sites in United States
- Volunteers
- 362 people
- Sponsor
- AiCuris Anti-infective Cures AG
Herpes Labialis
Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis
Purpose of this study is to determine the safety and efficacy of topical applications of NB-001 as compared to placebo for the treatment of recurrent herpes labialis.
- Trial name
- NCT00453401
- Testing
- NB-001
- Where
- 28 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- NanoBio Corporation
Herpes Labialis
Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis
A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).
- Trial name
- NCT00297011
- Testing
- valacyclovir+clobetasol gel
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Utah
Herpes Labialis
Immune Evidence to the Consumption of Lactobacillus GG and FOS Consumption in Patients With Herpes Labialis
Herpes labialis (HL) is the result of the presence of a virus called HSV-1 and is a common disease. Because of its visibility due to cold sores it has a serious impact on social life.
- Trial name
- EVIM2 (NCT03310294)
- Testing
- Prebiotics and Probiotics
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Sprim Advanced Life Sciences
Recurrent Herpes Labialis
An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis
BOR15001L7 is a natural product. The primary objective of this study is to demonstrate its non-inferiority to docosanol 10% based on the healing time of cold sores in patients with recurrent herpes labialis.
- Trial name
- NCT03977792
- Testing
- BOR15001L7, Docosanol Cream 10%
- Volunteers
- 164 people
- Sponsor
- Laboratoire Boreaderme Inc.
Herpes Labialis
Iontophoretic Application of Acyclovir Gel to Treat Cold Sores
Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the sites where the herpes virus is replicating.
- Trial name
- NCT00469300
- Testing
- Iontophoretic delivery of acyclovir
- Where
- 13 sites in United States
- Volunteers
- 810 people
- Sponsor
- Transport Pharmaceuticals
Intense-exuberant Stomach Fire Syndrom, Acute Pericoronitis
Effectiveness and Clinical Mechanism of Huanglian-Jiedu Decoction in Patients With Intense-exuberant Stomach Fire Syndrome
This clinical research focus on evaluating the effectiveness of Huanglian-Jiedu Decoction in patients with intense-exuberant stomach fire syndrome (one of the common TCM syndrome)of acute pericoronitis,minor recurrent aphthous…
- Conditions
- Intense-exuberant Stomach Fire Syndrom, Acute Pericoronitis, Recurrent Aphthous Stomatitis, Recurrent Herpes Simplex Labialis
- Trial name
- NCT03469232
- Testing
- Huanglian-Jiedu Decoction
- Where
- 3 sites in China
- Volunteers
- 240 people
- Sponsor
- China Academy of Chinese Medical Sciences
Herpes Labialis
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between.
- Trial name
- NCT00306293
- Testing
- valacyclovir
- Where
- 18 sites in United States
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Recurrent Herpes Simplex Labialis
A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis
Demonstrate the safety and efficacy of NB-001 in subjects with recurrent herpes labialis (RHL).
- Trial name
- SHaRCS (NCT01321359)
- Testing
- Vehicle versus NB-001
- Where
- 35 sites in United States
- Volunteers
- 907 people, healthy volunteers welcome
- Sponsor
- NanoBio Corporation
Herpes Labialis
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection
This is a phase II, double-blind, randomised, controlled, multicentre trial of topical HDIT101 versus placebo. HSV-1-positive patients with at least 6 orolabial herpes lesions in the last 12 months can be included.
- Trial name
- MATCH-1 (NCT04539483)
- Testing
- HDIT101 (blinded therapy), Photo documentation of orolabial herpes lesions, Completion of questionnaires (patient-reported outcomes)
- Where
- 5 sites in Germany
- Volunteers
- 761 people
- Sponsor
- Heidelberg ImmunoTherapeutics GmbH
Herpes Labialis, Herpes Simplex Virus
A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis
Background: A cold sore is usually a blistering rash on or near the lips, caused by infection with herpes simplex virus. After the first infection, the virus goes into a dormant (inactive) state, but it can continue to cause cold…
- Trial name
- NCT00913692
- Testing
- Glutamine, Glycine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Recurrent Herpes Labialis
Place Controlled Study to Treat Recurrent Herpes Labialis.
About 80% of the worldwide population is positive on HSV antibodies. In the United States the lifetime prevalence of recurrent herpes labialis is estimated at 20% to 40%, with approximately 100 million episodes occurring in the…
- Trial name
- NCT00914745
- Testing
- Ointment
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich
Herpes Labialis
Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
To test the safety of Xerese (acyclovir and hydrocortisone)Cream 5%/1% for the treatment of recurrent cold sores in children ages 6-11yrs after 5 days of treatment.
- Trial name
- NCT01574612
- Testing
- acyclovir/hydrocortisone cream
- Where
- 10 sites in United States
- Volunteers
- 54 people
- Sponsor
- Meda Pharmaceuticals
Herpes Labialis
Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis
The purpose of this study is to determine whether ME-609 is more efficient than acyclovir and placebo for the treatment of recurrent herpes labialis.
- Trial name
- NCT00361881
- Testing
- ME-609, acyclovir in ME-609 vehicle, Vehicle
- Where
- United States
- Volunteers
- 1,443 people
- Sponsor
- Medivir
Oral Herpes Simplex
Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection
The purpose of this study is to determine if a new treatment is effective for the treatment of recurrent symptomatic oral herpes virus infections.
- Trial name
- NCT01308424
- Testing
- BTL TML HSV
- Where
- 4 sites in United States
- Volunteers
- 171 people
- Sponsor
- Beech Tree Labs, Inc.
Herpes Labialis
Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients
The purpose of this study is to evaluate the episode duration of a herpes labialis recurrence in immunocompromised patients treated with ME-609 or Acyclovir.
- Trial name
- NCT00735761
- Testing
- ME-609, Acyclovir in ME-609 vehicle (5% acyclovir)
- Volunteers
- 201 people
- Sponsor
- Medivir